Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: Risk factors for multidrug-resistance

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 6, 2009, Pages 403-407

  Serefhanoglu, Kivanc ^a   Turan, Hale ^a   Timurkaynak, Funda Ergin ^a   Arslan, Hande ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

ESBLs; Multidrug resistance; Risk factors

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAMASE; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BLOOD CULTURE; BLOODSTREAM INFECTION; CASE CONTROL STUDY; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; INFECTION RISK; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; ADULT; AGED; BIOSYNTHESIS; CROSS INFECTION; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI INFECTION; FEMALE; KLEBSIELLA INFECTION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 77953938480     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000600003     Document Type: Article

References (33)

1. Bush K. Is it important to identify extended spectrum β-lactamase producing isolates? Eur J Clin Microb Infect Dis. 1996;15:361-364.
2. Jeong SH, Bae IK, Kwon SB, et al. Investigation of extendedspectrum β-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli in Korea. Lett Appl Microbiol. 2004;39:41-47.
3. Mendelson G, Hait V, Ben-Israel J, et al. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis. 2005;24:17-22.
4. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-686.
5. Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System. J Antimicrob Chemother. 2001;50:945-952.
6. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extendedspectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30:473-478.
7. Hyle EP, Lipworth AD, Zaoutis TE, et al. Risk Factors for Increasing Multidrug Resistance among Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella Species. Clin Infect Dis. 2005;40:1317-1324.
8. Bell JM, Turnidge JD, Gales AC, et al. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis. 2002;42:193-198.
9. Spanu T, Luzzaro F, Perilli M, et al. and The Italian ESBL Study Group. Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother. 2002;46:196-202.
10. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections. Am J Infect Control. 1988;16:128-140.
11. Baur AW, Kirby WMM, Sherris JC, et al. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Path. 1966;45:493-496.
12. Performance standards for antimicrobial susceptibility testing; ninth informational supplement, 1999;M100-S9. National Committee for Clinical Laboratory Standards, Wayne, PA7.
13. Jacoby, GA, Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 1996;34:908-911.
14. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement, 2004;M100-S14, p. 24, Table 2A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Knaus WA, Drapier EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
16. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34:20-28.
17. Villegas MV, Correa A, Perez F, et al. The Colombian Nosocomial Resistance Study Group. Prevalence and characterization of extended-spectrum β-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian Hospitals. Diagn Microbiol Infect Dis. 2004;49:217-222.
18. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: Risk Factors, molecular epidemiology, and clinical outcome. Antimicrob Agents and Chemother. 2006;50:498-504.
19. Itokazu GS, Quinn JP, Bell-Dixon C, et al. Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 1996;23:779-784.
20. Lautenbach EBL, Bilker SWB, Patel JB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis. 2001;33:1288-1294.
21. Yu WL, Jones RN, Hollis RJ, et al. Molecular epidemiology of extended-spectrum β-lactamase producing, fluoroquinoloneresistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol. 2002;40:4666-4669.
22. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended-spectrum β-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42:925-934.
23. Lucet JC, Chevret S, Decre D, et al. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis. 1996;22:430-436.
24. Podschun, R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11:589-603.
25. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007;29:630-636.
26. Shah AA, Hasan F, Ahmed S, et al. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β-lactamases. Res Microbiol. 2004;155:409-421.
27. Marra AR,Wey SB, Castelo A, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extendedspectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis. 2006;6:24-32.
28. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460-463.
29. Yu WL, Pfaller MA, Winokur PL, et al. Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumonia. Emerg Infect Dis. 2002;8:522-524.
30. Schwaber MJ, Navon-Venezia S, Schwartz D, et al. High Levels of Antimicrobial Coresistance among Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antýmicrob Agents and Chemother. 2005;49:2137-2139.
31. Villegasa MV, Correaa A, Pereza F, et al. Prevalence and characterization of extended-spectrum β-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagn Microbiol Infect Dis. 2004;49:217-222.
32. DiPersioa JR, Deshpandeb LM, Biedenbachb DJ, et al. Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis. 2005;51:1-7.
33. Chlebicki MP, Oh HML. Extended-spectrum β-lactamases in clinical isolates of E. coli and Klebsiella spp. in a Singopore hospital: Clinical spectrum. Ann Acad Med Singopore. 2004;33:302-306.